A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis
E
Erik Imel, MD
Primary Investigator
Overview
We are doing this research study because we are trying to learn more about a drug called Denosumab in children with glucocorticoid-induced osteoporosis.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Glucocorticoid-induced Osteoporosis
-
Age: Between 5 Years - 17 Years
-
Gender: All
Inclusion Criteria
Clinical diagnosis of GiOP
Other criteria exists-please contact study team
Updated on
17 Apr 2024.
Study ID: 1809456517